(RTTNews) - Shares of NextCure Inc. (NXTC) are up nearly 30% at $6.60 in premarket trading on Friday, following encouraging preclinical data of its brittle bone disease drug candidate, NC605.

GLP-1 drugs, such as Ozempic and Wegovy, may slightly increase the risk of osteoporosis, gout, and the rare metabolic bone disease osteomalacia, a recent study suggests. As these conditions are all ...

SEATTLE -- Treating osteogenesis imperfecta with the parathyroid hormone teriparatide followed by zoledronic acid, a bisphosphonate, failed to reduce the risk of fractures compared with standard ...

H, three teams of researchers have regrown bone and cartilage, even entire knees, in animal studies. Human trials are not far ...

A potential treatment developed by AstraZeneca for hypophosphatasia has showed positive results in phase III trials, the ...

Osteoporosis — a significant drop in bone density — can lead to fractures and disability if left untreated. Here are ways to ...

Multiple myeloma is a serious but often misunderstood disease. It affects thousands of people every year, including many in Black communities, where the risk is nearly twice as high as ...